Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

Alice L. Yu, Andrew L. Gilman, M. Fevzi Özkaynak et al. · New England Journal of Medicine · 2010 · 1.8K citations · Full text

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

E O’Brien, Nely Wigler, Moshe Inbar et al. · Annals of Oncology · 2004 · 1.7K citations · Full text

Liposomal Doxorubicin Hcl, Metastatic Breast Cancer, Oncology +8

Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project

Wendy B. London, Victoria Castel, Tom Monclair et al. · Journal of Clinical Oncology · 2011 · 325 citations

Passive versus Active Tumor Targeting Using RGD- and NGR-Modified Polymeric Nanomedicines

Sijumon Kunjachan, Robert Pola, Felix Gremse et al. · Nano Letters · 2014 · 307 citations · Full text

Nanotherapeutics, Engineering, Ngr-modified Polymeric Nanomedicines +19

Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.

Fabio Pastorino, Chiara Brignole, Danilo Marimpietri et al. · PubMed · 2003 · 297 citations

Tumor Biology, Drug Targeting, Oncology +15